| Zynyz (retifanlimab-dlwr) / Incyte |
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II. |
|
|
| Not yet recruiting | 2 | 66 | Europe | Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide) | Institut Bergonié, Incyte Biosciences International Sarl | retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04] | | | | |
PERELI, NCT06389799: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma |
|
|
| Not yet recruiting | 2 | 33 | Europe | Pemigatinib, Retifanlimab | Lund University Hospital | Dedifferentiated Liposarcoma | 12/27 | 12/28 | | |
| Recruiting | 2 | 66 | Europe | Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab | Institut Bergonié, Incyte Biosciences International Sàrl | Resectable Sarcoma | 03/25 | 10/27 | | |
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma |
|
|
| Active, not recruiting | 2 | 42 | US | INCMGA00012, Palbociclib | Memorial Sloan Kettering Cancer Center, Incyte Corporation | Well-differentiated/Dedifferentiated Liposarcoma | 06/25 | 06/25 | | |
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma |
|
|
| Active, not recruiting | 1/2 | 67 | US | Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel | Memorial Sloan Kettering Cancer Center, Incyte Corporation | Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult | 09/25 | 09/25 | | |
